192 related articles for article (PubMed ID: 21116002)
21. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
[TBL] [Abstract][Full Text] [Related]
22. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
[TBL] [Abstract][Full Text] [Related]
23. Rasburicase: future directions in tumor lysis management.
Hochberg J; Cairo MS
Expert Opin Biol Ther; 2008 Oct; 8(10):1595-604. PubMed ID: 18774926
[TBL] [Abstract][Full Text] [Related]
24. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Cheuk DK; Chiang AK; Chan GC; Ha SY
Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561
[TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
Martens KL; Khalighi PR; Li S; White AA; Silgard E; Frieze D; Estey E; Garcia DA; Hingorani S; Li A
Leuk Res; 2020 Feb; 89():106298. PubMed ID: 31945598
[TBL] [Abstract][Full Text] [Related]
26. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Cammalleri L; Malaguarnera M
Int J Med Sci; 2007 Mar; 4(2):83-93. PubMed ID: 17396159
[TBL] [Abstract][Full Text] [Related]
27. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
Herrington JD; Dinh BC
J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
[TBL] [Abstract][Full Text] [Related]
28. A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.
Eng S; Lee CS; Ahn S; Sharma A
J Oncol Pharm Pract; 2020 Mar; 26(2):338-344. PubMed ID: 31088218
[TBL] [Abstract][Full Text] [Related]
29. Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome.
Jeha S; Pui CH
Contrib Nephrol; 2005; 147():69-79. PubMed ID: 15604607
[TBL] [Abstract][Full Text] [Related]
30. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
McBride A; Lathon SC; Boehmer L; Augustin KM; Butler SK; Westervelt P
Pharmacotherapy; 2013 Mar; 33(3):295-303. PubMed ID: 23456733
[TBL] [Abstract][Full Text] [Related]
31. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Vines AN; Shanholtz CB; Thompson JL
Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
[TBL] [Abstract][Full Text] [Related]
32. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome.
Bessmertny O; Robitaille LM; Cairo MS
Curr Pharm Des; 2005; 11(32):4177-85. PubMed ID: 16375739
[TBL] [Abstract][Full Text] [Related]
33. Use of single-dose rasburicase in an obese female.
Arnold TM; Reuter JP; Delman BS; Shanholtz CB
Ann Pharmacother; 2004 Sep; 38(9):1428-31. PubMed ID: 15292497
[TBL] [Abstract][Full Text] [Related]
34. Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration.
Darmon M; Guichard I; Vincent F
J Clin Oncol; 2011 Jan; 29(3):e67-8; author reply e69. PubMed ID: 21149649
[No Abstract] [Full Text] [Related]
35. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
Gupta G; Seth T; Garg V; Juneja R; Mahapatra M; Datta SK; Upadhyay AD; Saxena R
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e99-e104. PubMed ID: 33039358
[TBL] [Abstract][Full Text] [Related]
36. Rasburicase in cancer-related hyperuricemia.
Rodriguez M; Campara M; Haaf C
Drugs Today (Barc); 2011 Aug; 47(8):591-603. PubMed ID: 21850282
[TBL] [Abstract][Full Text] [Related]
37. Risk-based management strategy and outcomes of tumor lysis syndrome in children with leukemia/lymphoma: Analysis from a resource-limited setting.
Gopakumar KG; Seetharam S; Km JK; Nair M; Rajeswari B; Cs G; Vr P; Thankamony P
Pediatr Blood Cancer; 2018 Dec; 65(12):e27401. PubMed ID: 30101454
[TBL] [Abstract][Full Text] [Related]
38. Managing malignancy-associated hyperuricemia with rasburicase.
Cheson BD; Dutcher BS
J Support Oncol; 2005; 3(2):117-24. PubMed ID: 15796443
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
Pei Y; Li Y; Liang Y; Xu L; Huang X; Li Y; Tang W; Jiang X
Int J Clin Pharm; 2020 Dec; 42(6):1440-1446. PubMed ID: 32974856
[TBL] [Abstract][Full Text] [Related]
40. Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
Shaikh SA; Marini BL; Hough SM; Perissinotti AJ
J Oncol Pharm Pract; 2018 Apr; 24(3):176-184. PubMed ID: 28077046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]